{"algorithm_version": "v0.6.0", "applied_rules": {"base_min_final_score": 68.0, "min_bullish_analyses": 2, "min_confidence": 0.62, "min_final_score": 70.0, "min_liquidity_avg_volume": 750000, "regime": "mixed", "regime_score_delta": 2.0}, "benchmark": "SPY", "catalysts": ["October 20, 2026: Genmab drew attention after reporting third-quarter DARZALEX net trade sales of approximately $4.239 billion, supporting royalty income.", "Recent Phase 3 data for epcoritamab (EPKINLY) plus R-CHOP showed a statistically significant progression-free-survival benefit and a 51% reduction in the risk of progression or death in newly diagnosed diffuse large B-cell lymphoma.", "Strong DARZALEX sales boost royalty income and highlight commercial strength.", "Positive Phase 3 and Phase 2 trial results support future growth in oncology.", "Phase 3 trial for EPKINLY showed a 51% reduction in disease progression risk in a common type of blood cancer, a major clinical win."], "company_name": "Genmab A/S", "conviction": "high", "data_quality": 0.855, "date": "2026-10-20", "favorable_models_count": 3, "final_confidence": 0.7165700378441217, "final_score": 75.53866666666667, "generated_at": "2026-10-20T07:30:00.008177-04:00", "horizon": "intraday", "models_answered": 3, "models_asked": 3, "quantitative_score": 55.93, "reason": null, "regulatory_warning": "This is automated, general-audience analysis published for informational purposes only. It is not a personal recommendation, not a promise of performance, and not an invitation to buy or sell any financial instrument. Every investment can lose value, and past results do not predict future ones.", "risks": ["The stock has already risen strongly, increasing the risk of profit-taking or a sell-the-news reaction.", "Genmab remains heavily reliant on DARZALEX royalty income, while future sales erosion and pipeline execution are significant risks.", "Recent rally could lead to profit-taking or short-term volatility.", "Conflicting analyst estimates may create uncertainty.", "The stock is already up about 11% over the past month, so some investors may take profits rather than push it higher."], "shortfalls": [], "status": "signal", "summary": "The near-term bias is bullish because strong DARZALEX sales and positive oncology trial results provide fresh fundamental support. However, the recent rally and conflicting analyst estimates create a meaningful risk of volatility or profit-taking in the next U.S. session.", "ticker": "GMAB", "timezone": "Europe/Zurich", "watchlist": []}